At a glance
ClinicalIndex Comparison RecordPhase 1Completed· 25 enrolled
Drug / intervention
BI 425809drug
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
Non-randomised, Open Label, Sequential-group Study to Assess the Pharmacokinetics and Pharmacodynamic Effect of Different Multiple Oral Doses of BI 425809 in Healthy Male Volunteers
In Brief
A Phase 1 clinical trial evaluating BI 425809 for Healthy. Completed, enrolled 25 participants across 1 site.
Detailed Summary
To assess the exposure of BI 425809 in cerebrospinal fluid relative to plasma as well as safety and tolerability, and to evaluate the effect of different doses of BI 425809 on biomarkers levels in cerebrospinal fluid.
Study Details
Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsHealthy
CountriesBelgium
Collaborators--
Timeline
Phase 1CompletedFinished
201520162017201820192020202120222023202420252026
First PostedFeb 2015
Enrollment StartFeb 2015
Primary CompletionJun 2015
TodayJul 2026
First PostedFeb 13, 2015
Enrollment StartFeb 23, 2015
Primary CompletionJun 19, 2015
TodayJul 2, 2026
Enrollment to primary: 4 monthsPosted 11.4 years ago
Interventions
BI 425809drug
Tablet